ALL DISPATCHES

THE DAILY DISPATCH · NOVEMBER 17, 2026

AI funding cools as cyber, biology, and trials accelerate

ClinicalTrials.gov’s worldwide count for active gene, cell, mRNA, and SI trials stands at 21,558, with 60 new Wire signals and 13 new Cure research items arriving in the last 24 hours. At the capital/AI layer, an IMF warning about $1T in AI-linked circular financing—about two-thirds structured as debt—adds a debt-sensitivity brake to what had been an exuberant phase-transition narrative. Meanwhile, the applied intelligence layer is moving fast: an AI-fueled scan reported 28 zero-days found in 48 hours in Physical AI software, while Cure research announcements span computational antiviral design, prognostic glioma architecture clustering, and new live-cell imaging for locus-specific DNA repair dynamics. The combination—more targets, more signals, and still-growing experimental throughput—argues for disciplined optimism: progress is not slowing, but the financing and risk environment is becoming more selective. The window is still open.

THE SIGNAL

An AI-fueled scan reported 28 zero-days in 48 hours across Physical AI software.

THE STAKES

If vulnerabilities outpace defenses, deployment risk rises for AI systems that also power discovery and therapy—so faster patching becomes a direct humanity-level enabler of cure timelines.

THE WINDOW

Watch for whether debt-leaning AI circular deals tighten or re-route within days, and prioritize rapid remediation of the newly found zero-days before they compound.

21,558Global gene-cell-mRNA-SI trials
Preserved copy

This edition is queued for capture by the Internet Archive's Wayback Machine. Archivists are welcome to capture it directly.

Permalink: https://negativeresistance.com/dispatch/2026-11-17 · How this site is preserved